Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04155 (
pS2
)
1,234
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Estrogen-related receptor alpha
(
ERRalpha
) was identified as a gene related to estrogen receptor alpha (ERalpha) and belongs to a class of nuclear orphan receptors.
ERRalpha
binds to estrogen responsive element(s) (ERE) and is considered to be involved in modulation of estrogenic actions. However, biological significance of
ERRalpha
remains largely unknown. Therefore, we examined the expression of
ERRalpha
in human breast carcinoma tissues using immunohistochemistry (n = 102) and real-time reverse transcription-PCR (n = 30).
ERRalpha
immunoreactivity was detected in the nuclei of carcinoma cells in 55% of breast cancers examined, and relative immunoreactivity of
ERRalpha
was significantly (P = 0.0041) associated with the mRNA level. Significant associations were detected between ERalpha and ERE-containing estrogen-responsive genes, such as
pS2
(P < 0.0001) and EBAG9/RCAS1 (P = 0.0214), in breast carcinoma tissues. However, no significant association was detected between ERalpha and
pS2
(P = 0.1415) in the
ERRalpha
-positive cases (n = 56) or between ERalpha and EBAG9/RCAS1 (P = 0.8271) in the
ERRalpha
-negative group (n = 46).
ERRalpha
immunoreactivity was significantly associated with an increased risk of recurrence and adverse clinical outcome by both uni- (P = 0.0097 and P = 0.0053, respectively) and multi- (P = 0.0215 and P = 0.0118, respectively) variate analyses. A similar tendency was also detected in the group of breast cancer patients who received tamoxifen therapy after surgery. Results from our study suggest that
ERRalpha
possibly modulates the expression of ERE-containing estrogen-responsive genes, and
ERRalpha
immunoreactivity is a potent prognostic factor in human breast carcinoma.
...
PMID:Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. 1523 80